Comparative Pharmacology
Head-to-head clinical analysis: CARTROL versus METOPROLOL SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTROL versus METOPROLOL SUCCINATE.
CARTROL vs METOPROLOL SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors. Also suppresses renin release.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
25 to 100 mg orally once daily, titrated at weekly intervals as tolerated; maximum 400 mg/day
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 3-7 hours. Twice-daily dosing (metoprolol succinate) provides stable beta-blockade over 24 hours due to extended-release formulation, not due to half-life.
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Primarily renal (95% as metabolites, <5% unchanged). Three main metabolites: O-demethylated (active), α-hydroxylated (active), and O-demethylated and α-hydroxylated. Biliary/fecal excretion: <5%.
Category C
Category C
Beta-Blocker
Beta-Blocker